Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro is not cheap, and any UK private provider pricing it well below the market should prompt a question or two. Private tirzepatide treatment in the UK typically runs from around £149 to £375 per month depending on dose and provider — figures that shifted significantly after Eli Lilly raised its UK list price from 1 September 2025. Mounjaro is a prescription-only medicine, so every legal supply requires a clinical assessment by a qualified prescriber; cost is only one part of the picture. What you get for that money varies considerably, and that gap is where the real comparison lives.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It's a question our prescribers hear most weeks: someone has seen a headline figure online and wants to know whether it's legitimate. Sometimes it is. Often, that number is the medicine alone, before consultation fees, prescription charges, delivery and any aftercare access are added. Separate those out and the difference from a fully-inclusive provider can shrink fast or disappear altogether.
UK private weight-loss treatment pricing varies by dose, provider and what the price actually covers. The full breakdown of how Mounjaro is priced in the UK explains the structure in detail, but the short version is this: Eli Lilly's list price rose sharply from 1 September 2025, with higher doses now carrying a list price of around £330 per four-week pen. Providers set their own margins above that floor. What you pay privately depends on which dose you're prescribed and the service built around it, both of which matter.
Before assuming a lower figure represents a better deal, it is worth checking whether the consultation is charged separately, whether clinical review of repeat orders is included, and whether aftercare is available if you have questions between doses. A closer look at how providers compare on the full cost of treatment can help make those distinctions clearer.
nume does not run discount codes, promotional offers or subscription schemes. That is a deliberate position, not an oversight. The price shown on the treatment page is the complete price: consultation, prescription, the medicine, delivery and seven-day-a-week aftercare support. Nothing is billed separately afterwards.
Cheapest is not a race we entered. The reason is straightforward: Mounjaro is a prescription-only medicine, and the value of a service around it sits in clinical rigour rather than a low headline number. Every order, including every repeat, is reviewed by a named GPhC-registered Independent Prescriber before anything is dispensed. Identity is verified by photo ID, and weight is confirmed on a live video call. If a dose increase is requested, the prescriber checks for supporting evidence. Those steps cost time and skill, and they are what keeps the process safe.
You can see the full picture of how the service works on the Mounjaro treatment page, and verify our GPhC pharmacy registration (number 9012878) directly at the GPhC register. If you want to explore treatment options more broadly, the weight-loss treatment overview covers what is available and how eligibility is assessed. Our clinical team page sets out who reviews consultations.
The MHRA has warned publicly and repeatedly about counterfeit weight-loss pens sold online, including on social media. In October 2025, enforcement action in the UK uncovered the first illicit domestic manufacturing site producing fake tirzepatide pens; earlier operations in 2025 seized around 20 million doses of illegally traded weight-loss medicines with an estimated street value of around £45 million. Some fake pens have contained insulin. The MHRA's Yellow Card scheme accepts reports of suspect sellers as well as side effects.
The tell-tale pattern is consistent: medicines sold without a clinical assessment, prices far below what legitimate supply allows, discount codes offered by sellers with no verifiable pharmacy registration. A cheap Mounjaro listing that skips clinical assessment is not a bargain, it is a different product category entirely, one that carries real physical risk.
If you are looking at how pen pricing works at different doses, or specifically want to understand what a lower starting dose costs through a regulated UK provider, those pages set out the factual picture. The guide to buying Mounjaro safely in the UK covers the legitimacy checks worth running before committing to any provider. For the highest doses, the 15mg cost context is worth reading separately given how much list pricing shifted in late 2025.
The legal route to Mounjaro in the UK is a prescription following clinical assessment by a registered prescriber, dispensed through a pharmacy you can verify on the GPhC register. Price is one data point. Whether the supply is genuine, the assessment is real and the aftercare is available when you need it are the ones that actually keep you safe. Speak to our prescribers through a free consultation and we will assess whether treatment is clinically appropriate for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.